# FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

> **NCT00448019** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00448019
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448019, "FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00448019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*